Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 796

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 796
---
 totaled approximately $6,160,000as of September 30, 2024. |

| ii. | Has liquidation preferences over common stock; |

| iii. | Is convertible into common stock, at the option of the holder, subject to adjustments, as defined; and |

| iv. | For purposes of voting, each holder of outstanding shares of Preferred Stock is entitled to cast the number of votes equal to the number of whole shares of common stock into which the shares are convertible to. |

<div align='center'>F-74</div>

TUHURA BIOSCIENSES, INC AND SUBSIDIARY Notes to the condensed consolidated financial statements For the nine months ended September 30, 2024, and 2023 (Unaudited)

| v. | The holders of Series A and SeriesA-1Preferred Stock exclusively and voting together as a single class have the right to elect one Director of the Company. |

| vi. | A majority of all three classes of Preferred stock are required to amend the Articles of Incorporation or Bylaws, issue shares (unless they are junior to the Preferred stock), issue debt greater than $250,000, liquidate or dissolve the Company, or hold stock in an unaffiliated Company. |

In August 2024, the Company extended the exercise period of its common stock purchase warrants issued in connection with its Series A Preferred Stock (the “Series A Warrants”) for an additional six months, with a new expiry date of February 12, 2025. There were no other changes in the terms of the Series A Warrants. As a result, a deemed dividend to the holders of the Series A Warrants in the amount of $ 965,177 was recorded as an increase in the net loss attributable to the common stockholders for the nine months ended September 30, 2024. The incremental value associated with the warrant modification was determined using a Black-Sholes pricing model using the original terms of the warrants and the modified terms of the warrants and the following assumptions: expected term of approximately 0.1 - 0.6 years, dividend yield of 0.0 %, volatility of 75 % - 112%, and a risk free rate of 5.4 % to 5.5 %.

As of September 30, 2024, the Company has 59,648,400 warrants outstanding, of which 7,835,300 warrants were for services performed with respect to historical offerings and 18,797